| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | E3 ubiquitin-protein ligase TRIM58, 632-, Protein BIA2, Tripartite motif-containing protein 58, TRIM58 |
| Entrez GeneID | 25893 |
| WB Predicted band size | 54.8kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | This TRIM58 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 457-486 amino acids from the C-terminal region of human TRIM58. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是假设存在的3篇关于TRIM58抗体的参考文献及其摘要概括：
---
1. **文献名称**: *TRIM58 Acts as a Tumor Suppressor in Acute Myeloid Leukemia by Promoting Cell Differentiation*
**作者**: Zhang, Y. et al.
**摘要**: 本研究利用TRIM58抗体通过Western blot和免疫组化技术，发现TRIM58在急性髓系白血病(AML)患者中表达显著下调。实验表明，TRIM58通过调控细胞分化相关通路抑制白血病细胞增殖，提示其可能作为AML的潜在治疗靶点。
2. **文献名称**: *TRIM58 Modulates Ubiquitination in Colorectal Cancer via E3 Ligase Activity*
**作者**: Li, X. et al.
**摘要**: 作者通过TRIM58抗体进行免疫共沉淀(Co-IP)实验，揭示了TRIM58在结直肠癌中作为E3泛素连接酶的关键作用。研究发现，TRIM58通过泛素化降解致癌蛋白抑制肿瘤进展，其抗体被用于体内外功能验证。
3. **文献名称**: *TRIM58 Deficiency Disrupts Erythroid Maturation: Insights from Knockout Mouse Models*
**作者**: Wang, H. et al.
**摘要**: 该研究利用TRIM58抗体对基因敲除小鼠的红细胞进行免疫荧光和流式分析，证明TRIM58在红细胞成熟过程中调控细胞骨架蛋白泛素化。TRIM58缺失导致红细胞分化障碍，提示其在贫血病理机制中的作用。
---
注：上述文献为假设性示例，实际引用时需以真实发表的论文为准。建议通过PubMed或Google Scholar以关键词“TRIM58 antibody”、“TRIM58 function”检索最新文献。
TRIM58. a member of the tripartite motif (TRIM) protein family, functions as an E3 ubiquitin ligase involved in protein degradation via the ubiquitin-proteasome system. It plays roles in cell proliferation, differentiation, and apoptosis, with emerging links to cancer biology. TRIM58 is notably implicated in erythropoiesis, where it regulates erythroid cell maturation by targeting specific substrates for ubiquitination. Recent studies highlight its tumor-suppressive potential in various cancers, including hepatocellular carcinoma and non-small cell lung cancer, where its downregulation correlates with poor prognosis, metastasis, and drug resistance. This suppression is often attributed to promoter hypermethylation or transcriptional silencing in malignancies.
TRIM58 antibodies are essential tools for investigating its expression patterns, molecular interactions, and functional mechanisms. These antibodies enable techniques like Western blotting, immunohistochemistry, and immunofluorescence to assess TRIM58 localization and abundance in tissues or cell lines. Researchers also utilize them to explore TRIM58's role in ubiquitination cascades and its interplay with oncogenic or anti-apoptotic pathways. Clinically, TRIM58 antibodies hold diagnostic potential as biomarkers for cancer stratification or monitoring therapeutic responses. However, challenges remain in standardizing antibody specificity across experimental models. Ongoing research aims to clarify TRIM58's dual roles in different cellular contexts and its viability as a therapeutic target.
×
